Japanese Drug Maker To Seek New Trial For Parkinson’s Drug Approval
This article was originally published in PharmAsia News
Japan's Kyowa Hakko Kirin says it plans to put its Parkinson's disease drug through Phase III clinical trials later this year. The drug, KW-6002 (istradefylline), targets the brain's adenosine A2A receptor to prevent destruction of dopamine. The drug is to be used in conjunction with current treatments. The company failed in a bid to get U.S. approval last year when the FDA said it needed more data. Now that Phase II trials in Japan have been conducted, the company feels it is time to make a new approval attempt and is considering a license to another drug maker. (Click here for more - a subscription may be required
You may also be interested in...
Diabetes-related foot amputations are on the rise in the UK. Stada through its UK subsidiary Thornton & Ross is partnering with Diabetes UK to promote foot health and the benefits of using its leading OTC foot-care brand, Flexitol.
The company said its own calculations suggest a mid-November readout could yield a positive result, keeping it on track for an EUA before the end of 2020.
With COVID-19 continuing to wreak havoc in the EU just as throughout the globe, the European Commission is proposing new measures that will impact antigen test availability and use